a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer
|MFs / NAME||Price $||Chg $||Chg %|
|JPMorgan Growth Advantage R5|
|Loomis Sayles Small Cap Growth N|
|Cambiar International Equity Inv|
|Goldman Sachs Focused Value Instl|
|Invesco Comstock Select Y|
A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with FATE. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then FATE could also see price increases.